MedTrace Logo

A Clinical Trial Assessing Safety of MF101 for Hot Flushes

NCT01300078 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2011-06-02

No results posted yet for this study

Summary

This Phase 1, open label, randomized clinical trial will enroll 40 generally healthy, postmenopausal women aged 40-65 years old. Women will be randomized to one of two oral doses of MF101 for 4 weeks. Participants will be recruited at 3 clinical sites in the United States.

Conditions

Interventions

DRUG

MF101

MF101 10 g/day MF101 15 g/day

Sponsors & Collaborators

  • Bionovo

    lead INDUSTRY

Principal Investigators

  • Wulf Utian, PhD, DSc(Med), FRCOG, FACOG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
65 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-03-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01300078 on ClinicalTrials.gov